Net turnover in the second quarter was stable compared with the second quarter 2010, up 2.4% in local currencies to €786.2 million.
Strong growth was achieved in Asia-Pacific, Africa and Middle East (+80.8% in Q2, +68.8% in H1 in local currencies), Russia/CIS (+10.9% in Q2, +20.5% in H1 in local currencies) and Latin America (+5.5% in Q2, +10.0% in H1 in local currencies) continued to grow, offsetting the challenging conditions in the US and Western Europe.
Commenting on the company's second quarter performance, Nycomed CEO Håkan Björklund said: "We again saw the success of our increasing focus on emerging markets in the second quarter, with strong performances in areas such as Asia, Middle East and Latin America helping to offset anticipated declines in some of the more mature markets of Western Europe and the US.
We look forward to closing the agreement with Takeda for the acquisition of Nycomed announced in May and to creating a truly global pharmaceutical business equipped to meet the needs of patients, doctors and healthcare providers. Nycomed ends the first half of 2011 in excellent shape and looks forward to an even brighter future."
Nycomed is a privately owned global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio.
Its R&D is structured around collaborations. In-licensing and expanding in emerging markets are cornerstones of the company's growth strategy.
Nycomed employs 12,500 associates worldwide, and its products are sold in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US and Japan its products are available through best in class partners.
Headquartered in Zurich, Switzerland, the company generated total sales of € 3.2 billion in 2010 and an adjusted EBITDA of € 851 million.